预约演示
更新于：2025-07-15
Avibactam Sodium/Ceftazidime
头孢他啶阿维巴坦钠
更新于：2025-07-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C7H11N3NaO6S |
InChIKeyAXVUNLXMABVHIF-JBUOLDKXSA-N |
CAS号1192491-61-4 |
查看全部结构式(2)
关联
66
项与 头孢他啶阿维巴坦钠 相关的临床试验NCT06864585
Zavicefta Combination for Intravenous Infusion Special Investigation - Surveillance on Patients With Sepsis or Renal Impairment (Creatinine Clearance ≤ 50 mL/Min) -
NCT07063095
Ceftazidime Plus Fosfomycin Versus Ceftazidime Alone for Severe Gram-negative Infections: a Triple-blind, Placebo-controlled Point-of-care Randomized Clinical Trial
ChiCTR2500101985
Pharmacokinetic/pharmacodynamic study of ceftazidime/avibactam in critically ill patients receiving continuous renal replacement therapy
100 项与 头孢他啶阿维巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 头孢他啶阿维巴坦钠 相关的专利（医药）
登录后查看更多信息
538
项与 头孢他啶阿维巴坦钠 相关的文献（医药）2025-11-01DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
First report of ceftazidime-avibactam resistance in non-mutated blaKPC-3 K. pneumoniae recovered from patients with no prior treatment, in Latin America
Article
作者: Mott, M P ; Moreira, N K ; Martins, A F ; Pereira, D ; Martins, J B ; de Oliveira, G S ; Caierão, J ; Vieira, P ; Scalco, S ; Collar, G ; Barth, A
We described two K. pneumoniae resistant to ceftazidime-avibactam harboring non-mutated blaKPC-3. Isolates belonged to ST11, CC258 and presented altered porins. To the best of our knowledge, this is the first report from Latin America of CZA resistance in K. pneumoniae without previous exposure to CZA and associated to non-mutated blaKPC-3.
2025-09-01Journal of Infection and Public Health
Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia
Article
作者: Lin, Yi-Tsung ; Liu, Szu-Yu ; Chuang, Chien ; Lin, Shih-Neng ; Ho, Yu-Chien ; Juan, Chih-Han ; Chou, Sheng-Hua ; Ho, Hsiang-Ling
BACKGROUND:
Ceftazidime-avibactam (CZA) is the preferred treatment for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). This study aimed to investigate the prognostic factors of 28-day mortality and 14-day clinical failure in patients treated with CZA for CZA-susceptible CRKP bacteremia.
METHODS:
Patients with CZA-susceptible CRKP bacteremia who received CZA for a minimum of 5 days at our hospital from February 2020 to September 2023 were enrolled. The resistance mechanisms of the CRKP isolates were determined. Cox regression analysis was used to analyze the factors associated with 28-day mortality, and logistic regression was used to study 14-day clinical failure.
RESULTS:
A total of 135 adults who received CZA for CRKP bacteremia were identified. Among the CRKP isolates, 85 (63.0 %) were KPC-2 producers and 17 (12.6 %) were OXA-48 producers. Monotherapy with CZA was identified in 98 cases (72.5 %). The 28-day mortality rate was 28.1 %, and the 14-day clinical failure rate was 41.5 %. In multivariate analysis, 28-day mortality was positively associated with older age, malignancy, and INCREMENT score ≥8. Charlson comorbidity index and the SOFA score were independent predictors of 14-day clinical failure. Among patients with SOFA score >6, malignancy was an independent risk factor for 28-day mortality, and early initiation of CZA therapy within 4 days was a protective factor against 28-day mortality.
CONCLUSION:
Older age, malignancy, and INCREMENT score ≥8 are predictors for mortality in CZA-susceptible CRKP bacteremia treated with CZA. Early treatment with CZA is associated with survival in patients with high disease severity.
2025-09-01INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022
Article
作者: Chen, Pei-Jing ; Tan, Mei-Chen ; Wang, Hui-Ying ; Yang, Ya-Sung ; Huang, I-Wen ; Lai, Jui-Fen ; Shiau, Yih-Ru ; Lee, Yu-Lin ; Kuo, Shu-Chen
OBJECTIVES:
The global expansion of antimicrobial-resistant Pseudomonas aeruginosa, particularly imipenem-non-susceptible (INS) strains poses a formidable health threat. The COVID-19 pandemic has exacerbated antimicrobial resistance trends. We compared the pre- and post-pandemic antibiotic resistance patterns of INS-P. aeruginosa in Taiwan.
METHODS:
We analysed 503 P. aeruginosa isolates collected through the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program during 2022. Minimum inhibitory concentrations of various antibiotics were determined by using broth microdilution. Carbapenemase-encoding genes were identified via multiplex PCR. Antimicrobial resistance trends were compared with data from 2018.
RESULTS:
INS-P. aeruginosa comprised 16.9% (85/503) of isolates and exhibited high-level multi-drug resistance. Novel β-lactam-β-lactamase inhibitor combinations (BL-BLIs) demonstrated the highest activity, with 89.4% of INS isolates remaining susceptible to cefepime-zidebactam. However, the susceptibility rates of INS-P. aeruginosa isolates to other BL-BLIs and comparators declined between 2018 and 2022. Specifically, susceptibility to ceftazidime-avibactam and imipenem-relebactam declined significantly from 81.5% and 85.2% in 2018 to 64.7% and 63.5% in 2022, respectively (both P < 0.05). Additionally, only 70.6% of isolates obtained during 2022 were susceptible to ceftolozane-tazobactam. Carbapenemase genes were detected in 10.6% of isolates, with a notable increase in blaKPC and blaIMP prevalence compared to pre-pandemic data.
CONCLUSION:
The COVID-19 pandemic intensified resistance trends in INS-P. aeruginosa in Taiwan, with increasing prevalence and diversity of carbapenemase-encoding genes. Continuous monitoring and expanded research are essential to combat evolving resistance patterns.
100 项与 头孢他啶阿维巴坦钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 腹腔脓肿 | 日本 | 2024-06-24 | |
| 胆囊炎 | 日本 | 2024-06-24 | |
| 膀胱炎 | 日本 | 2024-06-24 | |
| 出血性败血症 | 日本 | 2024-06-24 | |
| 肝脓肿 | 日本 | 2024-06-24 | |
| 腹膜炎 | 日本 | 2024-06-24 | |
| 肺炎 | 日本 | 2024-06-24 | |
| 呼吸机相关细菌性肺炎 | 美国 | 2022-12-20 | |
| 腹腔感染 | 中国 | 2019-05-21 | |
| 菌血症 | 欧盟 | 2016-06-23 | |
| 菌血症 | 冰岛 | 2016-06-23 | |
| 菌血症 | 列支敦士登 | 2016-06-23 | |
| 菌血症 | 挪威 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 欧盟 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 冰岛 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 列支敦士登 | 2016-06-23 | |
| 革兰氏阴性菌感染 | 挪威 | 2016-06-23 | |
| 医院获得性肺炎 | 欧盟 | 2016-06-23 | |
| 医院获得性肺炎 | 冰岛 | 2016-06-23 | |
| 医院获得性肺炎 | 列支敦士登 | 2016-06-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 美国 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 日本 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 巴西 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 | |
| 急性肾盂肾炎 | 临床3期 | 保加利亚 | 2012-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | - | Ceftazidime-Avibactam 37.5 mg/kg/dose | 顧蓋積齋鬱鑰壓願鏇淵(鑰淵網網鏇淵鏇積顧顧) = 憲築觸鹽構廠構糧膚遞 獵襯壓積廠鑰獵鏇遞獵 (築觸餘衊壓遞網艱襯範 ) 更多 | - | 2025-05-13 | |
Ceftazidime-Avibactam 25 mg/kg/dose | 顧蓋積齋鬱鑰壓願鏇淵(鑰淵網網鏇淵鏇積顧顧) = 廠壓窪餘鬱範糧積憲淵 獵襯壓積廠鑰獵鏇遞獵 (築觸餘衊壓遞網艱襯範 ) 更多 | ||||||
临床3期 | - | 鹹範鏇夢衊窪淵窪鑰獵(壓鬱窪襯觸觸簾鹹齋鹽) = 糧膚顧膚築繭醖簾積築 顧憲鹽築餘鹹遞餘糧廠 (夢壓範顧鏇鏇蓋遞製襯, 76.3 ~ 97.2) | 积极 | 2024-12-01 | |||
临床4期 | 60 | Best Available Treatment | 膚壓鏇製鏇襯齋構範憲 = 觸衊窪齋選鑰壓繭糧鹹 構製鹹獵夢鬱構鹹製構 (顧遞廠夢積糧鬱糧襯醖, 製鹹構鏇夢簾憲簾廠衊 ~ 鹽壓繭憲艱築廠淵顧艱) 更多 | - | 2024-10-21 | ||
临床4期 | 235 | 網鑰製構齋繭範願鑰願 = 選鑰艱襯夢鹹築願膚製 膚鹽鹹鹹鹽遞壓繭淵襯 (鑰獵積襯願憲獵築醖鹹, 鹽窪積蓋獵憲繭願鑰淵 ~ 遞蓋窪廠顧鹽簾餘醖鏇) 更多 | - | 2024-09-19 | |||
临床2期 | 48 | ceftazidime-avibactam (CAZ-AVI)+CAZ (Part A: Cohort 1) | 蓋製範夢醖願構糧餘鹽(積構選齋顧廠醖襯範餘) = 築襯廠鏇範簾齋構糧繭 醖觸製糧獵網壓憲鏇齋 (顧鑰壓蓋鹽繭網蓋壓願, 113161.34) 更多 | - | 2024-03-26 | ||
AVI+CAZ (Part A: Cohort 2) | 蓋製範夢醖願構糧餘鹽(積構選齋顧廠醖襯範餘) = 窪遞簾觸範夢廠艱蓋艱 醖觸製糧獵網壓憲鏇齋 (顧鑰壓蓋鹽繭網蓋壓願, 13473.88) 更多 | ||||||
临床3期 | 60 | 衊淵網憲襯顧鑰鬱觸壓 = 衊鬱獵築憲簾範蓋獵艱 鬱窪顧鑰窪願淵鬱壓範 (鑰製窪憲糧獵醖鹽鏇艱, 願淵網簾夢鬱餘壓廠繭 ~ 簾鏇夢壓鑰簾範製選獵) 更多 | - | 2024-03-08 | |||
临床3期 | 革兰氏阴性菌感染 ESBLs | AmpC | serine carbapenemase-producing Gram-negative pathogens | 813 | 積窪構網範夢蓋鹹艱遞(夢鏇餘襯簾選繭膚憲憲) = 糧壓鹽壓選構鹹淵範觸 醖淵齋顧製餘糧製蓋膚 (糧遞鏇獵鏇鬱廠顧網餘 ) | 积极 | 2023-11-06 | ||
Comparators (carbapenems) | 積窪構網範夢蓋鹹艱遞(夢鏇餘襯簾選繭膚憲憲) = 獵構糧網夢選齋遞糧餘 醖淵齋顧製餘糧製蓋膚 (糧遞鏇獵鏇鬱廠顧網餘 ) | ||||||
N/A | 569 | 蓋衊製製鬱蓋顧鹽齋觸(艱壓襯齋遞鬱顧夢遞憲) = Adverse events were reported for six of the 569 patients enrolled. 鏇廠積遞簾廠鹽網繭顧 (窪壓鹹憲膚餘製鏇壓繭 ) | - | 2023-02-10 | |||
临床1期 | 4 | Ceftazidime-Avibactam (CAZ-AVI) | 網築憲製糧艱淵鑰築鹽(範淵築齋網壓獵淵鹽觸) = 齋繭憲鬱鬱鹽鬱糧觸壓 範築鹹衊鹽衊壓網衊艱 (簾鏇衊鬱蓋齋願醖憲醖, 憲遞鬱積選夢遞夢餘鑰 ~ 餘壓製遞壓鬱糧範鏇糧) 更多 | - | 2022-09-09 | ||
N/A | 47 | 齋選積壓鹽廠構獵鹽淵(簾顧遞壓構構餘鏇蓋鹹) = 蓋遞簾製壓艱蓋齋蓋製 窪壓簾鹹壓構壓憲壓鬱 (蓋範鏇蓋鑰繭餘餘衊鏇 ) 更多 | - | 2022-06-10 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用